Sanofi Active Ingredient Solutions API Supply, Custom Synthesis, API and Pharma Contract Manufacturing Solutions


Sanofi Active Ingredient Solutions is a contract development and manufacturing organisation (CDMO) specialising in active pharmaceutical ingredient (API) supply and custom synthesis.

The company is the new branding of Sanofi API third party business. More than 2,000 women and men are developing, manufacturing and supplying API and technological solutions for external customers and partners in 80 countries.

To do so, the company works with passion, pride and rigour, recognising that its products are the key contributor to therapeutic solutions, helping millions of people live life to its full potential, every day, all over the world.

For innovative pharmaceutical companies, from start-ups to big pharma companies, generics pure players and through its catalogue of high-quality active ingredients and its contract development and manufacturing organisation, the company delivers expertise and customised solutions that contribute to the success of your business.

As a global leader, Sanofi Active Ingredient Solutions has been supporting customers for decades with innovative, efficient and safe solutions, high-quality products and premium customer service.

Contract development and manufacturing services for medical drugs

Sanofi Active Ingredient Solutions offers pharmaceutical drug developers in more than 80 countries with API and technological solutions, supporting partners from process development to regulatory submission.

Its expertise covers multiple therapeutic areas for human and animal health, including corticosteroids, hormones, viral vectors, multi-step chemistry, opiates, prostaglandins and high-active products, as well as plasmids, oligosaccharides, peptides, oligosaccharides, biotechnologies and monoclonal antibodies (mAb).

Sanofi Active Ingredient Solutions partners with innovative companies ranging from start-ups to some of the biggest pharmaceutical players. Its catalogue of high-quality APIs and customised CDMO services delivers expertise and contributes to key therapeutic solutions that help millions of people.

The company has been supporting customers for decades with innovative, efficient and safe solutions, as well as high-quality products and customer service. It focuses on the continuous improvement of manufacturing processes to optimise output and meet client expectations.

Sanofi Active Ingredient Solutions’ synthesis API portfolio covers cardiovascular disease, metabolic disorders, analgesics and non-fluorinated glucocorticoids and derivatives (NSAID), as well as central nervous system (CNS) disorders and anaesthetics.

In the corticosteroids and hormones field, the company has more than 60 years of experience, and is a fully integrated corticoids manufacturer.

Clinical supply and commercial manufacturing for the biotech industry

Sanofi Active Ingredient Solutions has been providing biotech customers with services ranging from clinical supply to commercial manufacturing since 1985. Using its dedicated biotech platform, the company has gained a significant track record, working on an average of more than 70 batches per year.

The company has 25 years of experience in the field of oligosaccharides. Sanofi Active Ingredient Solutions’ analytical expertise guarantees purity and quality, while its robust supply chain is widely recognised.

Fermentation technologies, nutraceuticals, vitamins and probiotics

Sanofi Active Ingredient Solutions offers large-volume fermentation services and has proven expertise in nutraceuticals, vitamins and probiotics.

The company meets clients’ specific demands with the highest standards.

It has a long-standing expertise in organic chemistry with specific competencies in complex and long synthesis, as well as supports its customers’ projects from early phases through to validation campaigns.

APIs for human and animal health

Sanofi Active Ingredient Solutions is a world leader in the manufacturing of prostaglandins, with a strong historical background in process development and the scale-up of new chemical entities. Its portfolio includes 18 prostaglandin APIs.

The company’s production lines are multi-purpose, allowing quick and flexible developments and scale-ups, along with constant high quality. It also provides exhaustive regulatory support to its customers.

Sanofi Active Ingredient Solutions is the sole European vitamin B12 manufacturer, while its biotech API catalogue offers 14 APIs, including antibiotics and anti-tuberculosis.

Beyond the APIs, the company has developed a strong customer-oriented policy with a large range of possible specifications and customisations.

Opiates from poppy seeds to APIs

Sanofi Active Ingredient Solutions provides opiates in forms ranging from poppy seeds to APIs.

The company’s portfolio comprises 15 opiate APIs with applications in agronomic research, industrial and agricultural production, and distribution. It grows and harvests 10,000 ha of poppies each year.

Make an enquiry

Press Release

Sanofi and GSK to Unite in Vaccine Collaboration to Combat Covid-19

Sanofi and GSK are pleased to announce that they have signed a letter of intent to develop an adjuvanted vaccine for Covid-19, using new technology from both companies, to aid in addressing the ongoing pandemic.

Product and Services
White Papers

SANOFI Active Ingredient Solutions

Sanofi Active Ingredient Solutions have more than 2,000 people developing, manufacturing and supplying active pharmaceutical ingredients and technological solutions to external customers and partners in 80 countries.

Sanofi Active Ingredient Solutions

20, avenue Raymond Aron

92160 Antony Cedex



+33 1 55 71 26 34 +33 1 55 71 23 63

Sanofi Active Ingredient Solutions Images

Related Projects

Sanofi Manufacturing Plant, Goa, India

French pharmaceutical company Sanofi’s manufacturing facility in Goa, India, is located in the Verna Industrial Park, owned by Sanofi’s Indian arm Sanofi India, previously known as Aventis Pharma.

9 June 2020

Sanofi’s Vaccine Manufacturing Facility, Toronto, Ontario, Canada

French pharmaceutical company Sanofi Pasteur has unveiled plans to build a new vaccine manufacturing facility in Toronto, Ontario, Canada.

3 September 2018

Sanofi – Lonza Biologics Production Facility, Visp

Leading Switzerland-based biopharmaceuticals supplier Lonza and French life sciences firm Sanofi has established a joint venture (JV) to set up a large-scale biologics production facility in Visp, Switzerland.

16 January 2018

Sanofi Biologics Plant Expansion, Geel

Sanofi, a global healthcare leader based in France, is expanding its biologics plant in Belgium, to further develop its manufacturing and commercial production capabilities.

5 May 2016

Ash Stevens Riverview Facility

Michigan-based contract pharmaceutical manufacturing company Ash Stevens operates two facilities for API process development and production.

1 May 2013

Sanofi Lantus SoloSTAR Pen Assembly Plant, Yizhuang, Beijing

Sanofi China opened a new assembling and packaging facility for prefilled insulin devices in Beijing, China, in May 2012. The facility will produce the SoloSTAR insulin injection pens.

18 June 2012

Sanofi Pasteur R&D Centre

Sanofi Pasteur, the vaccine division of Sanofi, opened a new vaccine research and development centre in Toronto, Ontar

13 September 2011

Sanofi Pasteur Vaccine Plant, Val De Reuil, France

Sanofi Pasteur, the vaccines division of Sanofi Aventis, is focusing on a continuing technology upgrade and expansion. T

4 September 2008

Sanofi Pasteur Vaccine Production Plant, Swiftwater, Pennsylvania

Sanofi Pasteur, the vaccines business of Sanofi-Aventis, is one of the largest seasonal influenza vaccine producers in t

14 October 2007

Press Release

6 May 2020

Sanofi and GSK are pleased to announce that they have signed a letter of intent to develop an adjuvanted vaccine for Covid-19, using new technology from both companies, to aid in addressing the ongoing pandemic.

Read more
30 April 2020

Sanofi and Regeneron Pharmaceuticals have announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial investigating Kevzara® (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalised patients with serious respiratory illness as a result of Covid-19.

Read more
27 February 2020

Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential molecules responsible for the beneficial effects used in the composition of any drug.

Read more
18 December 2019

Sanofi is pleased to announce that it will be appearing at CPhI Japan on 16-18 March at Tokyo Big Sight in Tokyo, Japan.

Read more
10 October 2019

Sanofi Active Ingredient Solutions are pleased to announce we will be appearing at CPhI Worldwide on 5-7 November at Messe Frankfurt in Frankfurt, Germany.

Read more
19 February 2019

AGuIX® is an innovative nanoparticle discovered by NH TherAGuIX, a French start-up based in Lyon and created in 2015 by Géraldine Le Duc and Olivier Tillement.

Read more
2 October 2018

Sanofi CEPiA has announced that the company will now be known as Sanofi Active Ingredient Solutions.

Read more
10 May 2018

Sanofi has announced it will be attending a number of events this year.

Read more
15 May 2017

Sanofi CEPiA has announced a number of upcoming events where the company will be showcasing its products and services.

Read more
19 October 2016

Sanofi has experience with industrial development of all kinds of projects and brings new chemical entities to market.

Read more
19 April 2016

The Life Science Leader magazine has awarded CEPiA-Sanofi as a worldwide CMO Leader for the third year running.

Read more
12 April 2015

CEPIA-Sanofi has been awarded the CMO leadership award within the categories quality, reliability, productivity and innovation by Life Science Leader.

Read more

Regional Offices

Sanofi Active Ingredient Solutions

20, avenue Raymond Aron

92160 Antony Cedex



+33 1 55 71 26 34 +33 1 55 71 23 63
CEPiA US and Canada

55 Corporate Drive

08807 Bridgewater

New Jersey

United States of America

+1 908 981 4986
CEPiA Japan

20-2, Nishishinjuku 3-chome


163-1488 Tokyo


+81 3 6301 3450
CEPiA Eastern Europe and Turkey

Nitrianska 100

920 27 Hlohovec


+421 33 736 2810
CEPiA India

Aventis House

54/A, Sir Mathuradas Vasanji

400 093 Mumbai



+91 22 28278089
CEPiA China

Floor 30, Phase II, Plaza 66, No.1366 Nanjing

200040 Shanghai


+86 21 6288 1616 (Ext. 2804)
CEPiA Eastern Europe and Turkey

130 U Kabelovny


102 37


Czech Republic

CEPiA China

Kerry Center Tower 3

20F, 1228 Yan’An Road

Jing An District





Go Top